BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00077681" target="_blank" >RIV/00216224:14110/14:00077681 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10292786 RIV/00159816:_____/14:00061366 RIV/00064203:_____/14:10292786

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jaci.2014.02.028" target="_blank" >http://dx.doi.org/10.1016/j.jaci.2014.02.028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jaci.2014.02.028" target="_blank" >10.1016/j.jaci.2014.02.028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

Popis výsledku v původním jazyce

Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patientswith SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population).

Název v anglickém jazyce

BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

Popis výsledku anglicky

Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patientswith SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of allergy and clinical immunology

ISSN

0091-6749

e-ISSN

—

Svazek periodika

133

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

1134-1141

Kód UT WoS článku

000333531700025

EID výsledku v databázi Scopus

—